43 results on '"Putoczki, Tracy L."'
Search Results
2. Structures of the interleukin 11 signalling complex reveal gp130 dynamics and the inhibitory mechanism of a cytokine variant
- Author
-
Metcalfe, Riley D., Hanssen, Eric, Fung, Ka Yee, Aizel, Kaheina, Kosasih, Clara C., Zlatic, Courtney O., Doughty, Larissa, Morton, Craig J., Leis, Andrew P., Parker, Michael W., Gooley, Paul R., Putoczki, Tracy L., and Griffin, Michael D. W.
- Published
- 2023
- Full Text
- View/download PDF
3. S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer
- Author
-
Low, Ronnie Ren Jie, Fung, Ka Yee, Gao, Hugh, Preaudet, Adele, Dagley, Laura F., Yousef, Jumana, Lee, Belinda, Emery-Corbin, Samantha J., Nguyen, Paul M., Larsen, Rune H., Kershaw, Nadia J., Burgess, Antony W., Gibbs, Peter, Hollande, Frédéric, Griffin, Michael D. W., Grimmond, Sean M., and Putoczki, Tracy L.
- Published
- 2023
- Full Text
- View/download PDF
4. Necroptosis is dispensable for the development of inflammation-associated or sporadic colon cancer in mice
- Author
-
Alvarez-Diaz, Silvia, Preaudet, Adele, Samson, Andre L., Nguyen, Paul M., Fung, Ka Yee, Garnham, Alexandra L., Alexander, Warren S., Strasser, Andreas, Ernst, Matthias, Putoczki, Tracy L., and Murphy, James M.
- Published
- 2021
- Full Text
- View/download PDF
5. SIDT2 RNA Transporter Promotes Lung and Gastrointestinal Tumor Development
- Author
-
Nguyen, Tan A., Bieging-Rolett, Kathryn T., Putoczki, Tracy L., Wicks, Ian P., Attardi, Laura D., and Pang, Ken C.
- Published
- 2019
- Full Text
- View/download PDF
6. Loss of Bcl-G, a Bcl-2 family member, augments the development of inflammation-associated colorectal cancer
- Author
-
Nguyen, Paul M., Dagley, Laura F., Preaudet, Adele, Lam, Nga, Giam, Maybelline, Fung, Ka Yee, Aizel, Kaheina, van Duijneveldt, Gemma, Tan, Chin Wee, Hirokawa, Yumiko, Yip, Hon Yan K., Love, Christopher G., Poh, Ashleigh R., Cruz, Akshay D’, Burstroem, Charlotte, Feltham, Rebecca, Abdirahman, Suad M., Meiselbach, Kristy, Low, Ronnie Ren Jie, Palmieri, Michelle, Ernst, Matthias, Webb, Andrew I., Burgess, Tony, Sieber, Oliver M., Bouillet, Philippe, and Putoczki, Tracy L.
- Published
- 2020
- Full Text
- View/download PDF
7. Identification of Serum Biomarkers to Monitor Therapeutic Response in Intestinal-Type Gastric Cancer.
- Author
-
Dagley, Laura F., Yousef, Jumana, Preaudet, Adele, Loving, Andrea, Webb, Andrew I., Ernst, Matthias, and Putoczki, Tracy L.
- Subjects
STOMACH cancer ,END of treatment ,BIOMARKERS ,TUMOR markers ,TUMOR treatment - Abstract
There are a limited number of clinically useful serum biomarkers to predict tumor onset or treatment response in gastric cancer (GC). For this reason, we explored the serum proteome of the gp130
Y757F murine model of intestinal-type gastric cancer (IGC). We identified 30 proteins with significantly elevated expression in early gp130Y757F IGC and 12 proteins that were significantly elevated in late gp130Y757F IGC compared to age- and gender-matched wild-type mice. Within these signatures, there was an overlap of 10 proteins commonly elevated in both early- and late-stage disease. These results highlight the potential to identify serum biomarkers of disease stage. Since IGC in the gp130Y757F model can be reversed following therapeutic inhibition of Interleukin (IL)-11, we explored whether the protein signatures we identified could be used to monitor tumor regression. We compared two different therapeutic modalities and found 5 proteins to be uniquely differentially expressed between control animals and animals halfway through treatment, with 10 differentially expressed at the end of treatment. Our findings highlight the potential to identify reliable biomarkers to track IGC tumor regression in response to treatment. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
8. Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer
- Author
-
Johnstone, Cameron N., Chand, Ashwini, Putoczki, Tracy L., and Ernst, Matthias
- Published
- 2015
- Full Text
- View/download PDF
9. NLRP1 restricts butyrate producing commensals to exacerbate inflammatory bowel disease
- Author
-
Tye, Hazel, Yu, Chien-Hsiung, Simms, Lisa A., de Zoete, Marcel R., Kim, Man Lyang, Zakrzewski, Martha, Penington, Jocelyn S., Harapas, Cassandra R., Souza-Fonseca-Guimaraes, Fernando, Wockner, Leesa F., Preaudet, Adele, Mielke, Lisa A., Wilcox, Stephen A., Ogura, Yasunori, Corr, Sinead C., Kanojia, Komal, Kouremenos, Konstantinos A., De Souza, David P., McConville, Malcolm J., Flavell, Richard A., Gerlic, Motti, Kile, Benjamin T., Papenfuss, Anthony T., Putoczki, Tracy L., Radford-Smith, Graham L., and Masters, Seth L.
- Published
- 2018
- Full Text
- View/download PDF
10. Interleukin-11 Is the Dominant IL-6 Family Cytokine during Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically
- Author
-
Putoczki, Tracy L., Thiem, Stefan, Loving, Andrea, Busuttil, Rita A., Wilson, Nicholas J., Ziegler, Paul K., Nguyen, Paul M., Preaudet, Adele, Farid, Ryan, Edwards, Kirsten M., Boglev, Yeliz, Luwor, Rodney B., Jarnicki, Andrew, Horst, David, Boussioutas, Alex, Heath, Joan K., Sieber, Oliver M., Pleines, Irina, Kile, Benjamin T., Nash, Andrew, Greten, Florian R., McKenzie, Brent S., and Ernst, Matthias
- Published
- 2013
- Full Text
- View/download PDF
11. The Interleukin-11/IL-11 Receptor Promotes Glioblastoma Survival and Invasion under Glucose-Starved Conditions through Enhanced Glutaminolysis.
- Author
-
Stuart, Sarah F., Bezawork-Geleta, Ayenachew, Areeb, Zammam, Gomez, Juliana, Tsui, Vanessa, Zulkifli, Ahmad, Paradiso, Lucia, Jones, Jordan, Nguyen, Hong P. T., Putoczki, Tracy L., Licciardi, Paul V., Kannourakis, George, Morokoff, Andrew P., Achuthan, Adrian A., and Luwor, Rodney B.
- Subjects
GLIOBLASTOMA multiforme ,GENE expression ,CELL survival ,OVERALL survival ,CELL lines - Abstract
Glioblastoma cells adapt to changes in glucose availability through metabolic plasticity allowing for cell survival and continued progression in low-glucose concentrations. However, the regulatory cytokine networks that govern the ability to survive in glucose-starved conditions are not fully defined. In the present study, we define a critical role for the IL-11/IL-11Rα signalling axis in glioblastoma survival, proliferation and invasion when cells are starved of glucose. We identified enhanced IL-11/IL-11Rα expression correlated with reduced overall survival in glioblastoma patients. Glioblastoma cell lines over-expressing IL-11Rα displayed greater survival, proliferation, migration and invasion in glucose-free conditions compared to their low-IL-11Rα-expressing counterparts, while knockdown of IL-11Rα reversed these pro-tumorigenic characteristics. In addition, these IL-11Rα-over-expressing cells displayed enhanced glutamine oxidation and glutamate production compared to their low-IL-11Rα-expressing counterparts, while knockdown of IL-11Rα or the pharmacological inhibition of several members of the glutaminolysis pathway resulted in reduced survival (enhanced apoptosis) and reduced migration and invasion. Furthermore, IL-11Rα expression in glioblastoma patient samples correlated with enhanced gene expression of the glutaminolysis pathway genes GLUD1, GSS and c-Myc. Overall, our study identified that the IL-11/IL-11Rα pathway promotes glioblastoma cell survival and enhances cell migration and invasion in environments of glucose starvation via glutaminolysis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Characterization of the structure, expression and function of Pinus radiata D. Don arabinogalactan-proteins
- Author
-
Putoczki, Tracy L., Pettolino, Filomena, Griffin, Michael D. W., Möller, Ralf, Gerrard, Juliet A., Bacic, Antony, and Jackson, Sandra L.
- Published
- 2007
13. NF-κB1, NF-κB2 and c-Rel differentially regulate susceptibility to colitis-associated adenoma development in C57BL/6 mice
- Author
-
Burkitt, Michael D, Hanedi, Abdalla F, Duckworth, Carrie A, Williams, Jonathan M, Tang, Joseph M, OʼReilly, Lorraine A, Putoczki, Tracy L, Gerondakis, Steve, Dimaline, Rod, Caamano, Jorge H, and Pritchard, D Mark
- Published
- 2015
- Full Text
- View/download PDF
14. Elevated Dnmt3a Activity Promotes Polyposis in ApcMin Mice by Relaxing Extracellular Restraints on Wnt Signaling
- Author
-
Samuel, Michael S., Suzuki, Hiromu, Buchert, Michael, Putoczki, Tracy L., Tebbutt, Niall C., Lundgren–May, Therése, Christou, Aliki, Inglese, Melissa, Toyota, Minoru, Heath, Joan K., Ward, Robyn L., Waring, Paul M., and Ernst, Matthias
- Published
- 2009
- Full Text
- View/download PDF
15. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice
- Author
-
Thiem, Stefan, Pierce, Thomas P., Palmieri, Michelle, Putoczki, Tracy L., Buchert, Michael, Preaudet, Adele, Farid, Ryan O., Love, Chris, Catimel, Bruno, Lei, Zhengdeng, Rozen, Steve, Gopalakrishnan, Veena, Schaper, Fred, Hallek, Michael, Boussioutas, Alex, Tan, Patrick, Jarnicki, Andrew, and Ernst, Matthias
- Subjects
Cytokines -- Health aspects -- Physiological aspects -- Research ,Gastrointestinal tumors -- Risk factors -- Research -- Development and progression -- Genetic aspects ,Health care industry - Abstract
Gastrointestinal cancers are frequently associated with chronic inflammation and excessive secretion of IL-6 family cytokines, which promote tumorigenesis through persistent activation of the GP130/JAK/STAT3 pathway. Although tumor progression can be prevented by genetic ablation of Stat3 in mice, this transcription factor remains a challenging therapeutic target with a paucity of clinically approved inhibitors. Here, we uncovered parallel and excessive activation of mTOR complex 1 (mTORC1) alongside STAT3 in human intestinal-type gastric cancers (IGCs). Furthermore, in a preclinical mouse model of IGC, GP130 ligand administration simultaneously activated mTORC1/S6 kinase and STAT3 signaling. We therefore investigated whether mTORC1 activation was required for inflammation-associated gastrointestinal tumorigenesis. Strikingly, the mTORC1-specific inhibitor RAD001 potently suppressed initiation and progression of both murine IGC and colitis-associated colon cancer. The therapeutic effect of RAD001 was associated with reduced tumor vascularization and cell proliferation but occurred independently of STAT3 activity. We analyzed the mechanism of GP130-mediated mTORC1 activation in cells and mice and revealed a requirement for JAK and PI3K activity but not for GP130 tyrosine phosphorylation or STAT3. Our results suggest that GP130-dependent activation of the druggable PI3K/mTORC1 pathway is required for inflammation-associated gastrointestinal tumorigenesis. These findings advocate clinical application of PI3K/mTORC1 inhibitors for the treatment of corresponding human malignancies., Introduction During the multistep process of tumor formation conditions within the tissue microenvironment can influence the fate of premalignant cells. In inflammation-associated cancers, tumor promotion is thought to be facilitated [...]
- Published
- 2013
- Full Text
- View/download PDF
16. Intra-ring checking in Pinus radiata D. Don: the occurrence of cell wall fracture, cell collapse, and lignin distribution
- Author
-
Putoczki, Tracy L., Nair, Hema, Butterfield, Brian, and Jackson, Sandra L.
- Published
- 2007
- Full Text
- View/download PDF
17. Stat3: Linking inflammation to (gastrointestinal) tumourigenesis
- Author
-
Ernst, Matthias and Putoczki, Tracy L
- Published
- 2012
- Full Text
- View/download PDF
18. Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1−/− mice.
- Author
-
Low, Jun T., Ho, Gwo-Yaw, Scott, Mark, Tan, Chin Wee, Whitehead, Lachlan, Barber, Kathy, Yip, Hon Y. K., Dekkers, Johanna F., Hirokawa, Yumiko, Silke, John, Burgess, Antony W., Strasser, Andreas, Putoczki, Tracy L., and O'Reilly, Lorraine A.
- Published
- 2021
- Full Text
- View/download PDF
19. Emerging roles for the IL-6 family of cytokines in pancreatic cancer.
- Author
-
van Duijneveldt, Gemma, Griffin, Michael D. W., and Putoczki, Tracy L.
- Subjects
PANCREATIC cancer ,TREATMENT effectiveness ,CARCINOGENESIS ,CANCER cells - Abstract
Pancreatic cancer has one of the poorest prognoses of all malignancies, with little improvement in clinical outcome over the past 40 years. Pancreatic ductal adenocarcinoma is responsible for the vast majority of pancreatic cancer cases, and is characterised by the presence of a dense stroma that impacts therapeutic efficacy and drives pro-tumorigenic programs. More specifically, the inflammatory nature of the tumour microenvironment is thought to underlie the loss of anti-tumour immunity and development of resistance to current treatments. Inflammatory pathways are largely mediated by the expression of, and signalling through, cytokines, chemokines, and other cellular messengers. In recent years, there has been much attention focused on dual targeting of cancer cells and the tumour microenvironment. Here we review our current understanding of the role of IL-6, and the broader IL-6 cytokine family, in pancreatic cancer, including their contribution to pancreatic inflammation and various roles in pancreatic cancer pathogenesis. We also summarise potential opportunities for therapeutic targeting of these pathways as an avenue towards combating poor patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11.
- Author
-
Metcalfe, Riley D., Putoczki, Tracy L., and Griffin, Michael D. W.
- Subjects
INTERLEUKIN-27 ,FAMILY roles ,INTERFERONS ,LUNG diseases ,COMPREHENSION - Abstract
Cytokines are small signaling proteins that have central roles in inflammation and cell survival. In the half-century since the discovery of the first cytokines, the interferons, over fifty cytokines have been identified. Amongst these is interleukin (IL)-6, the first and prototypical member of the IL-6 family of cytokines, nearly all of which utilize the common signaling receptor, gp130. In the last decade, there have been numerous advances in our understanding of the structural mechanisms of IL-6 family signaling, particularly for IL-6 itself. However, our understanding of the detailed structural mechanisms underlying signaling by most IL-6 family members remains limited. With the emergence of new roles for IL-6 family cytokines in disease and, in particular, roles of IL-11 in cardiovascular disease, lung disease, and cancer, there is an emerging need to develop therapeutics that can progress to clinical use. Here we outline our current knowledge of the structural mechanism of signaling by the IL-6 family of cytokines. We discuss how this knowledge allows us to understand the mechanism of action of currently available inhibitors targeting IL-6 family cytokine signaling, and most importantly how it allows for improved opportunities to pharmacologically disrupt cytokine signaling. We focus specifically on the need to develop and understand inhibitors that disrupt IL-11 signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Could the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer?
- Author
-
Nguyen, Paul M. and Putoczki, Tracy L.
- Subjects
- *
STOMACH cancer , *CANCER cell proliferation , *CELL proliferation , *CELL populations , *TUMOR microenvironment - Abstract
• Gastric cancer is a leading cause of cancer related deaths. • A common feature of gastric cancers is an inflammatory microenvironment. • Cytokines are produced in gastric tumours by a range of cell populations. • IL-17 and IL-18 associated cytokines may represent a new therapeutic opportunity. Chronic inflammation is recognized as a key tumor-promoting factor in a number of epithelial cancers, including gastric cancer (GC). The production of pro-inflammatory cytokines in the tumor microenvironment by both the innate and the adaptive immune response can activate signaling pathways that are associated with increased cell survival and proliferation of cancer cells. Among the cytokines that have most commonly been linked to inflammation-associated cancers, are the Th17 cell-associated cytokines IL-17A, IL-23, IL-22, and the IL-1 family members IL-1β and IL-18. However, whether their contribution to inflammation-associated cancers is universal, or specific to individual types of cancers, remains to be elucidated. This review will explore our current understanding of the known roles of these cytokines in gastritis and discuss how their therapeutic inhibition may be useful for GC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Emerging roles for Interleukin-11 in disease.
- Author
-
Nguyen, Paul M., Abdirahman, Suad M., and Putoczki, Tracy L.
- Subjects
DISEASES ,BIOLOGY - Abstract
Interleukin (IL)-11 belongs to the IL-6 family of cytokines, discovered over 30 years ago. While early studies focused on the ability of IL-11 to stimulate megakaryocytopoiesis, the importance of this cytokine to inflammatory disease and cancers is only just beginning to be uncovered. This review outlines recent advances in our understanding of IL-11 biology, and highlights the development of novel therapeutics with the potential for clinical targeting of signaling by this cytokine in multiple diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.
- Author
-
Tan, Fiona H, Putoczki, Tracy L, Stylli, Stanley S, and Luwor, Rodney B
- Subjects
- *
HEAD & neck cancer , *NON-small-cell lung carcinoma , *CHRONIC myeloid leukemia , *GASTROINTESTINAL stromal tumors , *LYMPHOBLASTIC leukemia , *KINASE inhibitors , *DASATINIB - Abstract
Human malignancies are often the result of overexpressed and constitutively active receptor and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor-driven pathways. Several tyrosine kinases (ie, EGFR, FGFR, PDGFR, VEGFR), are aberrantly activated in most common tumors, including leukemia, glioblastoma, gastrointestinal stromal tumors, non-small-cell lung cancer, and head and neck cancers. Iclusig™ (ponatinib, previously known as AP24534) is an orally active multi-tyrosine kinase inhibitor and is currently approved by the US Food and Drug Administration for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, specifically targeting the BCR-ABL gene mutation, T315I. Due to ponatinib's unique multi-targeted characteristics, further studies have demonstrated its ability to target other important tyrosine kinases (FGFR, PDGFR, SRC, RET, KIT, and FLT1) in other human malignancies. This review focuses on the available data of ponatinib and its molecular targets for treatment in various cancers, with a discussion on the broader potential of this agent in other cancer indications. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. Th17 cell differentiation proceeds independently of IRF8.
- Author
-
Newman, Dane M, Leung, Patrick SK, Putoczki, Tracy L, Nutt, Stephen L, and Cretney, Erika
- Abstract
The transcriptional repressor/activator interferon regulatory factor 8 (IRF8) modulates the differentiation of a multitude of hematopoietic lineages. However, the role of IRF8 in CD4+ T‐cell development is less well defined, with a recent study implicating IRF8 as an intrinsic repressor of interleukin‐17 (IL‐17) expressing T helper type 17 (Th17) cell differentiation. Using an IRF8‐EGFP reporter strain we have confirmed that IRF8 is expressed in all T helper lineages, including Th17 cells. The loss of IRF8 did not affect Th17 differentiation in vitro, beyond a small increase in IL‐22 expression. Moreover, IRF8 deficiency did not enhance the Th17 immune response in experimental T‐cell transfer colitis. Together, these results suggest that IRF8 does not play an essential intrinsic role in Th17 cell differentiation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Mouse models for gastric cancer: Matching models to biological questions.
- Author
-
Poh, Ashleigh R, O'Donoghue, Robert J J, Ernst, Matthias, and Putoczki, Tracy L
- Subjects
MEDICAL care ,LABORATORY mice ,PROGNOSIS ,CARCINOGENS ,MORTALITY - Abstract
Gastric cancer is the third leading cause of cancer-related mortality worldwide. This is in part due to the asymptomatic nature of the disease, which often results in late-stage diagnosis, at which point there are limited treatment options. Even when treated successfully, gastric cancer patients have a high risk of tumor recurrence and acquired drug resistance. It is vital to gain a better understanding of the molecular mechanisms underlying gastric cancer pathogenesis to facilitate the design of new-targeted therapies that may improve patient survival. A number of chemically and genetically engineered mouse models of gastric cancer have provided significant insight into the contribution of genetic and environmental factors to disease onset and progression. This review outlines the strengths and limitations of current mouse models of gastric cancer and their relevance to the pre-clinical development of new therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease?
- Author
-
Nguyen, Paul M., Putoczki, Tracy L., and Ernst, Matthias
- Subjects
- *
INFLAMMATORY bowel disease treatment , *PHYSIOLOGICAL effects of cytokines , *STAT proteins , *INTERLEUKIN-11 , *INTERLEUKIN-22 , *INTERLEUKIN-6 , *IMMUNE response - Abstract
The gastrointestinal tract is lined by a single layer of epithelial cells that secrete mucus toward the lumen, which collectively separates the immune sentinels in the underlying lamina propria from the intestinal microflora to prevent aberrant immune responses. Inflammatory bowel disease (IBD) describes a group of autoimmune diseases that arise from defects in epithelial barrier function and, as a consequence, aberrant production of inflammatory cytokines. Among these, interleukin (IL)-6, IL-11, and IL-22 are elevated in human IBD patients and corresponding mouse models and, through activation of the JAK/STAT3 pathway, can both propagate and ameliorate disease. In particular, cytokine-mediated activation of STAT3 in the epithelial lining cells affords cellular protection, survival, and proliferation, thereby affording therapeutic opportunities for the prevention and treatment of colitis. In this review, we focus on recent insights gained from therapeutic modulation of the activities of IL-6, IL-11, and IL-22 in models of IBD and advocate a cautionary approach with these cytokines to minimize their tumor-promoting activities on neoplastic epithelium. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. IL-11 signaling as a therapeutic target for cancer.
- Author
-
Putoczki, Tracy L and Ernst, Matthias
- Published
- 2015
- Full Text
- View/download PDF
28. The structure of human interleukin-11 reveals receptor-binding site features and structural differences from interleukin-6.
- Author
-
Putoczki, Tracy L., Dobson, Renwick C. J., and Griffin, Michael D. W.
- Subjects
- *
INTERLEUKIN-11 , *INTERLEUKIN-6 , *CYTOKINES , *BLOOD platelet disorders , *GASTROINTESTINAL cancer , *CRYSTAL structure , *BLOOD disease treatment - Abstract
Interleukin (IL)-11 is a multifunctional member of the IL-6 family of cytokines. Recombinant human IL-11 is administered as a standard clinical treatment for chemotherapy-induced thrombocytopaenia. Recently, a new role for IL-11 signalling as a potent driver of gastrointestinal cancers has been identified, and it has been demonstrated to be a novel therapeutic target for these diseases. Here, the crystal structure of human IL-11 is reported and the structural resolution of residues previously identified as important for IL-11 activity is presented. While IL-11 is thought to signal via a complex analogous to that of IL-6, comparisons show important differences between the two cytokines and it is suggested that IL-11 engages GP130 differently to IL-6. In addition to providing a structural platform for further study of IL-11, these data offer insight into the binding interactions of IL-11 with each of its receptors and the structural mechanisms underlying agonist and antagonist variants of the protein. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
29. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.
- Author
-
Ung, Nelson, Putoczki, Tracy L., Stylli, Stanley S., Ng, Irvin, Mariadason, John M., Chan, Timothy A., Hong-Jian Zhu, and Luwor, Rodney B.
- Published
- 2014
- Full Text
- View/download PDF
30. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids.
- Author
-
Low, Ronnie Ren Jie, Lim, Wei Wen, Nguyen, Paul M., Lee, Belinda, Christie, Michael, Burgess, Antony W., Gibbs, Peter, Grimmond, Sean M., Hollande, Frédéric, and Putoczki, Tracy L.
- Subjects
PANCREATIC tumors ,ADENOCARCINOMA ,CULTURES (Biology) ,CELL physiology ,DUCTAL carcinoma ,TISSUES ,CELL lines - Abstract
Simple Summary: Patients diagnosed with pancreatic cancer have very few treatment options. In order to identify new treatment opportunities, and develop new drugs for clinical use, appropriate model systems that take into account the complexities of a tumor are required. In this review, we summarize the current and emerging opportunities to accurately model pancreatic cancer using organoid technologies. We highlight the need for continued development of these complex model systems in order to inform personalized treatment. Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. While immortalized cancer cell lines and genetically engineered murine models have increased our understanding of PDAC tumorigenesis, they do not recapitulate inter- and intra-patient heterogeneity. PDAC patient derived organoid (PDO) biobanks have overcome this hurdle, and provide an opportunity for the high throughput screening of potential new therapies. This review provides a summary of the PDAC PDO biobanks established to date, and discusses how they have advanced our understanding of PDAC biology. Looking forward, the development of coculturing techniques for specific immune or stromal cell populations will enable a better understanding of the crosstalk that occurs within the tumor microenvironment, and the impact of this crosstalk on treatment response. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival.
- Author
-
Huang, Qiutong, Jacquelot, Nicolas, Preaudet, Adele, Hediyeh-zadeh, Soroor, Souza-Fonseca-Guimaraes, Fernando, McKenzie, Andrew N. J., Hansbro, Philip M., Davis, Melissa J., Mielke, Lisa A., Putoczki, Tracy L., Belz, Gabrielle T., and Moretta, Lorenzo
- Subjects
CARCINOGENESIS ,ANIMAL experimentation ,BIOLOGICAL models ,COLON tumors ,IMMUNITY ,INFLAMMATION ,LYMPHOCYTES ,MACHINE learning ,MICE ,RECTUM tumors ,SURVIVAL ,DISEASE progression - Abstract
Simple Summary: Colorectal cancer is the second leading cause of cancer-related death worldwide. The immune system plays a key role in controlling tumour onset and development. However, our immune system is complex and includes many different cell types which differently impact colorectal cancer outcomes. In this study, we investigated the function of the specialised type 2 innate lymphoid cells (ILC2) in colorectal cancer development and progression. We found that ILC2 infiltrate colorectal tumours and their presence was associated with reduced tumour burden in mice. In patients, this infiltration correlated with improved overall survival. Collectively, our work reveals that ILC2s are beneficial to colorectal cancer outcomes. Chronic inflammation of the gastrointestinal (GI) tract contributes to colorectal cancer (CRC) progression. While the role of adaptive T cells in CRC is now well established, the role of innate immune cells, specifically innate lymphoid cells (ILCs), is not well understood. To define the role of ILCs in CRC we employed complementary heterotopic and chemically-induced CRC mouse models. We discovered that ILCs were abundant in CRC tumours and contributed to anti-tumour immunity. We focused on ILC2 and showed that ILC2-deficient mice developed a higher tumour burden compared with littermate wild-type controls. We generated an ILC2 gene signature and using machine learning models revealed that CRC patients with a high intratumor ILC2 gene signature had a favourable clinical prognosis. Collectively, our results highlight a critical role for ILC2 in CRC, suggesting a potential new avenue to improve clinical outcomes through ILC2-agonist based therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Loss of NFKB1 Results in Expression of Tumor Necrosis Factor and Activation of Signal Transducer and Activator of Transcription 1 to Promote Gastric Tumorigenesis in Mice.
- Author
-
Low, Jun T., Christie, Michael, Ernst, Matthias, Dumoutier, Laure, Preaudet, Adele, Ni, Yanhong, Griffin, Michael D.W., Mielke, Lisa A., Strasser, Andreas, Putoczki, Tracy L., and O'Reilly, Lorraine A.
- Abstract
Activity of nuclear factor κB transcription factors and signaling via signal transducer and activator of transcription (STAT) are frequently altered in gastric cancer cells. Mice lacking NFKB1 (Nfkb1
–/– mice) develop invasive gastric cancer, and their gastric tissues have increased levels of cytokines, such as interleukin (IL) 6, IL22, IL11, and tumor necrosis factor (TNF), as well as increased activation of STAT1. We investigated whether these cytokines were required for STAT1 activation in gastric tissues of mice and critical for gastric tumorigenesis. We crossed Nfkb1–/– mice with Il6–/– , Il22–/– , Il11Rα–/– , and Tnf–/– mice. Stomach tissues from compound mutant mice were analyzed by histology, immunoblotting, and RNA sequencing. Lymphoid, myeloid, and epithelial cells were isolated from stomachs, and the levels of cytokines were determined by flow cytometric analysis. Nfkb1–/– mice developed gastritis, oxyntic atrophy, gastric dysplasia, and invasive tumors, whereas Nfkb1–/– Stat1–/– mice did not, even when followed for as long as 2 years. The levels of Il6 , Il11 , Il22 , and Tnf messenger RNA were increased in the body and antrum of the stomachs from Nfkb1–/– mice, from 3-6 months of age. However, Nfkb1–/– Il6–/– , Nfkb1–/– Il22–/– , and Nfkb1–/– Il11Rα–/– mice still developed gastric tumors, although the absence of IL11 receptor (IL11R) significantly reduced development of invasive gastric tumors. Stomachs from Nfkb1–/– Tnf–/– mice exhibited significantly less gastritis and oxyntic atrophy and fewer tumors than Nfkb1–/– mice. This correlated with reduced activation of STAT1 and STAT3 and fewer numbers of T cells and B cells infiltrating the gastric body. Loss of STAT1 or TNF significantly reduced expression of PD-L1 on epithelial and myeloid (CD11b+ ) cells in the gastric mucosa of Nfkb1–/– mice—indeed, to the levels observed on the corresponding cells from wild-type mice. In studies of gastric tumor development in knockout mice, we found that loss of NFKB1 causes increased expression of TNF in the stomach and thereby drives activation of STAT1, resulting in an inflammatory immune response and the development of gastric cancer. IL11R appears to be required for the progression of gastric tumors to the invasive stage. These findings suggest that inhibitors of TNF, and possibly also inhibitors of IL11/IL11Rα, might be useful in the treatment of gastric cancer. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
33. A Biobank of Colorectal Cancer Patient-Derived Xenografts.
- Author
-
Abdirahman, Suad M., Christie, Michael, Preaudet, Adele, Burstroem, Marie C. U., Mouradov, Dmitri, Lee, Belinda, Sieber, Oliver M., and Putoczki, Tracy L.
- Subjects
ANIMAL experimentation ,BIOLOGICAL models ,COLON tumors ,METASTASIS ,MICE ,GENETIC mutation ,RECTUM tumors ,TISSUE banks ,XENOGRAFTS - Abstract
Colorectal cancer (CRC) is a challenging disease, with a high mortality rate and limited effective treatment options, particularly for late-stage disease. Patient-derived xenografts (PDXs) have emerged as an informative, renewable experimental resource to model CRC architecture and biology. Here, we describe the generation of a biobank of CRC PDXs from stage I to stage IV patients. We demonstrate that PDXs within our biobank recapitulate the histopathological and mutation features of the original patient tumor. In addition, we demonstrate the utility of this resource in pre-clinical chemotherapy and targeted treatment studies, highlighting the translational potential of PDX models in the identification of new therapies that will improve the overall survival of CRC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
34. Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth.
- Author
-
Thilakasiri, Pathum, Huynh, Jennifer, Poh, Ashleigh R, Tan, Chin Wee, Nero, Tracy L, Tran, Kelly, Parslow, Adam C, Afshar‐Sterle, Shoukat, Baloyan, David, Hannan, Natalie J, Buchert, Michael, Scott, Andrew Mark, Griffin, Michael DW, Hollande, Frederic, Parker, Michael W, Putoczki, Tracy L, Ernst, Matthias, and Chand, Ashwini L
- Abstract
Excessive signaling through gp130, the shared receptor for the interleukin (IL)6 family of cytokines, is a common hallmark in solid malignancies and promotes their progression. Here, we established the in vivo utility of bazedoxifene, a steroid analog clinically approved for the treatment of osteoporosis, to suppress gp130‐dependent tumor growth of the gastrointestinal epithelium. Bazedoxifene administration reduced gastric tumor burden in gp130Y757F mice, where tumors arise exclusively through excessive gp130/STAT3 signaling in response to the IL6 family cytokine IL11. Likewise, in mouse models of sporadic colon and intestinal cancers, which arise from oncogenic mutations in the tumor suppressor gene Apc and the associated β‐catenin/canonical WNT pathway, bazedoxifene treatment reduces tumor burden. Consistent with the proposed orthogonal tumor‐promoting activity of IL11‐dependent gp130/STAT3 signaling, tumors of bazedoxifene‐treated Apc‐mutant mice retain excessive nuclear accumulation of β‐catenin and aberrant WNT pathway activation. Likewise, bazedoxifene treatment of human colon cancer cells harboring mutant APC did not reduce aberrant canonical WNT signaling, but suppressed IL11‐dependent STAT3 signaling. Our findings provide compelling proof of concept to support the repurposing of bazedoxifene for the treatment of gastrointestinal cancers in which IL11 plays a tumor‐promoting role. Synopsis: Inhibition of gp130‐receptor/STAT3 activity confers anti‐tumor effects in mouse models of gastrointestinal cancers. This effect is recapitulated in mice treated with bazedoxifene, an FDA‐approved drug for osteoporosis treatment, supporting its repurposing as treatment in gastrointestinal cancers. First proof‐of‐concept demonstration that bazedoxifene, an FDA‐approved drug for postmenopausal osteoporosis, inhibits the growth of gastric and colon cancers using three independent mouse models.Mechanistically, this arises from the capacity of bazedoxifene to systemically inhibit gp130/STAT3 signalling as demonstrated in the gp130Y757F mouse model of intestinal‐type gastric cancer.This data provides a strong rationale to support future clinical efforts for repurposing bazedoxifene as an inhibitor of gp130/STAT3 signaling. Inhibition of gp130‐receptor/STAT3 activity confers anti‐tumor effects in mouse models of gastrointestinal cancers. This effect is recapitulated in mice treated with bazedoxifene, an FDA‐approved drug for osteoporosis treatment, supporting its repurposing as treatment in gastrointestinal cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth.
- Author
-
Tan, Fiona H., Putoczki, Tracy L., Lou, Jieqiong, Hinde, Elizabeth, Hollande, Frédéric, Giraud, Julie, Stylli, Stanley S., Paradiso, Lucia, Zhu, Hong-Jian, Sieber, Oliver M., and Luwor, Rodney B.
- Subjects
- *
COLON tumor prevention , *ANTINEOPLASTIC agents , *CELLULAR signal transduction , *COLON tumors , *DRUG resistance , *EPIDERMAL growth factor , *INTERLEUKINS , *NEUROTRANSMITTER uptake inhibitors , *PROTEIN kinase inhibitors , *JANUS kinases , *IN vivo studies , *PHARMACODYNAMICS , *THERAPEUTICS ,TUMOR prevention ,RECTUM tumors - Abstract
Signal transducer and activator of transcription 3 (STAT3) signaling is a major driver of colorectal cancer (CRC) growth, however therapeutics, which can effectively target this pathway, have so far remained elusive. Here, we performed an extensive screen for STAT3 inhibitors among a library of 1167 FDA-approved agents, identifying Ponatinib as a lead candidate. We found that Ponatinib inhibits STAT3 activity driven by EGF/EGFR, IL-6/IL-6R and IL-11/IL-11R, three major ligand/receptor systems involved in CRC development and progression. Ponatinib was able to inhibit CRC migration and tumor growth in vivo. In addition, Ponatinib displayed a greater ability to inhibit STAT3 activity and mediated superior anti-proliferative efficacy compared to five FDA approved SRC and Janus Kinase (JAK) inhibitors. Finally, long-term exposure of CRC cells to Ponatinib, Dasatinib and Bosutinib resulted in acquired resistance to Dasatinib and Bosutinib occurring within six weeks. However, acquired resistance to Ponatinib was observed after long-term exposure of >4 months. Overall, our results identify a novel anti-STAT3 property of Ponatinib and thus, Ponatinib offers a potential therapeutic strategy for CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
36. STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics.
- Author
-
Zulkifli, Ahmad A., Tan, Fiona H., Putoczki, Tracy L., Stylli, Stanley S., and Luwor, Rodney B.
- Subjects
- *
STAT proteins , *EPIDERMAL growth factor receptors , *CANCER patients , *TYROSINE , *EARLY detection of cancer - Abstract
Several EGFR inhibitors are currently undergoing clinical assessment or are approved for the clinical management of patients with varying tumour types. However, treatment often results in a lack of response in many patients. The majority of patients that initially respond eventually present with tumours that display acquired resistance to the original therapy. A large number of receptor tyrosine and intracellular kinases have been implicated in driving signaling that mediates this tumour resistance to anti-EGFR targeted therapy, and in a few cases these discoveries have led to overall changes in prospective tumour screening and clinical practice (K-RAS in mCRC and EGFR T790M in NSCLC). In this mini-review, we specifically focus on the role of the STAT3 signaling axis in providing both intrinsic and acquired resistance to inhibitors of the EGFR. We also focus on STAT3 pathway targeting in an attempt to overcome resistance to anti-EGFR therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
37. Elevated Dnmt3a Activity Promotes Polyposis in Apc Min Mice by Relaxing Extracellular Restraints on Wnt Signaling.
- Author
-
Samuel, Michael S., Suzuki, Hiromu, Buchert, Michael, Putoczki, Tracy L., Tebbutt, Niall C., Lundgren–May, Therése, Christou, Aliki, Inglese, Melissa, Toyota, Minoru, Heath, Joan K., Ward, Robyn L., Waring, Paul M., and Ernst, Matthias
- Subjects
ENZYME regulation ,POLYPS ,MULTIENZYME complexes ,LABORATORY mice ,MOLECULAR relaxation ,CELLULAR signal transduction ,DNA ,METHYLATION ,REVERSE transcriptase polymerase chain reaction - Abstract
Background & Aims: Aberrant DNA methylation is a common early event in neoplasia, but it is unclear how this relates to dysregulation of DNA (cytosine-5) methyltransferases (Dnmts). Here we use knock-in transgenic mice to investigate the consequences of intestinal epithelium-specific overexpression of de novo Dnmt3a. Methods: A novel gene targeting strategy, based on the intestinal epithelium-specific, uniform expression of the A33 glycoprotein, is employed to restrict Dnmt3a overexpression in homozygous A33
Dnmt3a mutant mice. Results: A33Dnmt3a mice infrequently develop spontaneous intestinal polyps. However, when genetically challenged, tumor multiplicity in A33Dnmt3a ;ApcMin compound mice is 3-fold higher than in ApcMin mice. Although we observe a requirement for spontaneous loss of heterozygosity of the adenomatous polyposis coli (Apc) gene to trigger tumorigenesis in ApcMin mice, lesions in A33Dnmt3a ;ApcMin mice frequently retain the wild-type Apc allele. However, epithelia from normal mucosa and polyps of A33Dnmt3a ;ApcMin mice show hypermethylation-mediated transcriptional silencing of the Wnt antagonists Sfrp5, and to a lesser extent, Sfrp1 and increased nuclear β-catenin alongside activation of the Wnt-target gene Axin2/Conductin. Conversely, enforced Sfrp5 expression suppresses canonical Wnt-signaling more effectively in wild-type than in ApcMin cells. Conclusions: Aberrant activation of the canonical Wnt pathway, either by mono-allelic Apc loss or transcriptional silencing of Sfrp5 is largely insufficient to promote polyposis, but epistatic interactions between these genetic and epigenetic events enables initiation and promotion of disease. This mechanism is likely to play a role in human colorectal cancer, because we also show that elevated DNMT3A expression coincides with repressed SFRP5 and enhanced AXIN2/CONDUCTIN expression in paired patient biopsies. [Copyright &y& Elsevier]- Published
- 2009
- Full Text
- View/download PDF
38. The structure of the extracellular domains of human interleukin 11α receptor reveals mechanisms of cytokine engagement.
- Author
-
Metcalfe, Riley D., Aizel, Kaheina, Zlatic, Courtney O., Nguyen, Paul M., Morton, Craig J., Daisy Sio-Seng Lio, Heung-Chin Cheng, Dobson, Renwick C. J., Parker, Michael W., Gooley, Paul R., Putoczki, Tracy L., and Griffin, Michael D. W.
- Subjects
- *
INTERLEUKIN receptors , *CELL membranes , *MOLECULAR dynamics , *CRYSTAL structure - Abstract
Interleukin (IL) 11 activates multiple intracellular signaling pathways by forming a complex with its cell surface α-receptor, IL-11Rα, and the β-subunit receptor, gp130. Dysregulated IL-11 signaling has been implicated in several diseases, including some cancers and fibrosis. Mutations in IL-11Rα that reduce signaling are also associated with hereditary cranial malformations. Here we present the first crystal structure of the extracellular domains of human IL-11Rα and a structure of human IL-11 that reveals previously unresolved detail. Disease-associated mutations in IL-11Rα are generally distal to putative ligand-binding sites. Molecular dynamics simulations showed that specific mutations destabilize IL-11Rα and may have indirect effects on the cytokine-binding region. We show that IL-11 and IL-11Rα form a 1:1 complex with nanomolar affinity and present a model of the complex. Our results suggest that the thermodynamic and structural mechanisms of complex formation between IL-11 and IL-11Rα differ substantially from those previously reported for similar cytokines. This work reveals key determinants of the engagement of IL-11 by IL-11Rα that may be exploited in the development of strategies to modulate formation of the IL-11-IL-11Rα complex. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
39. Characterization of Blimp-1 function in effector regulatory T cells.
- Author
-
Cretney, Erika, Leung, Patrick SK., Trezise, Stephanie, Newman, Dane M., Rankin, Lucille C., Teh, Charis E., Putoczki, Tracy L., Gray, Daniel HD., Belz, Gabrielle T., Mielke, Lisa A., Dias, Sheila, and Nutt, Stephen L.
- Subjects
- *
CELLULAR immunity , *TRANSCRIPTION factors , *T cells , *GENE expression , *CELL differentiation - Abstract
Regulatory T (T reg ) cells maintain immunological tolerance in steady-state and after immune challenge. Activated T reg cells can undergo further differentiation into an effector state that highly express genes critical for T reg cell function, including ICOS, TIGIT and IL-10, although how this process is controlled is poorly understood. Effector T reg cells also specifically express the transcriptional regulator Blimp-1 whose expression overlaps with many of the canonical markers associated with effector T reg cells, although not all ICOS + TIGIT + T reg cells express Blimp-1 or IL-10. In this study, we addressed the role of Blimp-1 in effector T reg cell function. Mice lacking Blimp-1 specifically in T reg cells mature normally, but succumb to a multi-organ inflammatory disease later in life. Blimp-1 is not required for T reg cell differentiation, with mutant mice having increased numbers of effector T reg cells, but regulated a suite of genes involved in cell signaling, communication and survival, as well as being essential for the expression of the immune modulatory cytokine IL-10. Thus, Blimp-1 is a marker of effector T reg cells in all contexts examined and is required for the full functionality of these cells during aging. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model.
- Author
-
Thiem, Stefan, Eissmann, Moritz F., Elzer, Joachim, Jonas, Anna, Putoczki, Tracy L., Poh, Ashleigh, Nguyen, Paul, Preaudet, Adele, Flanagan, Dustin, Vincan, Elizabeth, Waring, Paul, Buchert, Michael, Jarnicki, Andrew, and Ernst, Matthias
- Subjects
- *
STAT proteins , *STOMACH tumors , *NEOPLASTIC cell transformation , *GENE expression in mammals , *TREFOIL factors , *TAMOXIFEN , *GENETICS , *DIAGNOSIS - Abstract
About 5% to 10% of human gastric tumors harbor oncogenic mutations in the KRAS pathway, but their presence alone is often insufficient for inducing gastric tumorigenesis, suggesting a requirement for additional mutagenic events or microenvironmental stimuli, including inflammation. Assessing the contribution of such events in preclinical mouse models requires Cre recombinase-mediated conditional gene expression in stem or progenitor cells of normal and transformed gastric epithelium. We therefore constructed a bacterial artificial chromosome containing transgene (Tg), comprising the regulatory elements of the trefoil factor 1 (Tffl) gene and the tamoxifen-inducible Cre recombinase (CreERT2)-coding sequence. The resulting Tg (Tff1-CreERT2) mice were crossed with mice harboring conditional oncogenic mutations in Kras or Braf. The administration of tamoxifen to the resulting adult Tg(Tff1-CreERT2);KrasLSL-G12D/+ and Tg(Tff1-CreERT2)BrafLSL-V600E/+ mice resulted in gastric metaplasia, inflammation, and adenoma development, characterized by excessive STAT3 activity. To assess the contribution of STAT3 to the spontaneously developing gastric adenomas in gp130F/F mice, which carry a knockin mutation in the Il6 signal transducer (Il6st), we generated Tg(Tff1-CreERT2); Stat3fl/fl;gp130F/F mice that also harbor a conditional Stat3 knockout allele and found that tamoxifen administration conferred a significant reduction in their tumor burden. Conversely, excessive Kras activity in Tg(Tff1-CreERT2);KrasLSL-G12D/+;gp130F/F mice promoted more extensive gastric inflammation, metaplastic transformation, and tumorigenesis than observed in Tg(Tff1- CreERT2);KrasLSL-G12D/+ mice. Collectively, our findings demonstrate that advanced gastric tumorigenesis requires oncogenic KRAS or BRAF in concert with aberrant STAT3 activation in epithelial precursor cells of the glandular stomach, providing a new conditional model of gastric cancer in which to investigate candidate therapeutic targets and treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. Epithelial gp130/Stat3 functions: An intestinal signaling node in health and disease.
- Author
-
Ernst, Matthias, Thiem, Stefan, Nguyen, Paul M., Eissmann, Moritz, and Putoczki, Tracy L.
- Subjects
- *
CELLULAR signal transduction , *STAT proteins , *EPITHELIAL cells , *WOUND healing , *GASTROINTESTINAL system injuries , *TUMOR growth , *NEOPLASTIC cell transformation , *INTERLEUKIN-11 - Abstract
Highlights: [•] Epithelial Stat3 signaling promotes wound-healing of the gastrointestinal lining. [•] Aberrant gp130/Stat3 signaling supports the growth of gastric and intestinal tumors. [•] Interleukin-11 is a more potent driver of gastrointestinal tumorigenesis than IL6. [•] Therapeutic interference with IL11 signaling blocks gastrointestinal tumor growth. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
42. Emerging roles for IL-11 in inflammatory diseases.
- Author
-
Fung, Ka Yee, Louis, Cynthia, Metcalfe, Riley D., Kosasih, Clara C., Wicks, Ian P., Griffin, Michael D.W., and Putoczki, Tracy L.
- Subjects
- *
CHRONIC obstructive pulmonary disease , *SYSTEMIC scleroderma , *PATHOGENESIS , *RHEUMATOID arthritis , *ASTHMA - Abstract
Interleukin-11 (IL-11) is a cytokine that has been strongly implicated in the pathogenesis of fibrotic diseases and solid malignancies. Elevated IL-11 expression is also associated with several non-malignant inflammatory diseases where its function remains less well-characterized. Here, we summarize current literature surrounding the contribution of IL-11 to the pathogenesis of autoimmune inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, diabetes and systemic sclerosis, as well as other chronic inflammatory conditions such as periodontitis, asthma, chronic obstructive pulmonary disease, psoriasis and colitis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
43. Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression.
- Author
-
Poh, Ashleigh R., Love, Christopher G., Masson, Frederick, Preaudet, Adele, Tsui, Cary, Whitehead, Lachlan, Monard, Simon, Khakham, Yelena, Burstroem, Lotta, Lessene, Guillaume, Sieber, Oliver, Lowell, Clifford, Putoczki, Tracy L., O'donoghue, Robert J.j., and Ernst, Matthias
- Subjects
- *
HEMATOPOIETIC stem cells , *COLON cancer treatment , *HEMATOLOGIC malignancies , *MACROPHAGE activation , *XENOGRAFTS - Abstract
Summary Aberrant activation of the SRC family kinase hematopoietic cell kinase (HCK) triggers hematological malignancies as a tumor cell-intrinsic oncogene. Here we find that high HCK levels correlate with reduced survival of colorectal cancer patients. Likewise, increased Hck activity in mice promotes the growth of endogenous colonic malignancies and of human colorectal cancer cell xenografts. Furthermore, tumor-associated macrophages of the corresponding tumors show a pronounced alternatively activated endotype, which occurs independently of mature lymphocytes or of Stat6-dependent Th2 cytokine signaling. Accordingly, pharmacological inhibition or genetic reduction of Hck activity suppresses alternative activation of tumor-associated macrophages and the growth of colon cancer xenografts. Thus, Hck may serve as a promising therapeutic target for solid malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.